HUE040274T2 - Heteroarilamidok a proteinaggregáció inhibitoraiként - Google Patents

Heteroarilamidok a proteinaggregáció inhibitoraiként

Info

Publication number
HUE040274T2
HUE040274T2 HUE15705417A HUE15705417A HUE040274T2 HU E040274 T2 HUE040274 T2 HU E040274T2 HU E15705417 A HUE15705417 A HU E15705417A HU E15705417 A HUE15705417 A HU E15705417A HU E040274 T2 HUE040274 T2 HU E040274T2
Authority
HU
Hungary
Prior art keywords
heteroarylamides
inhibitors
protein aggregation
aggregation
protein
Prior art date
Application number
HUE15705417A
Other languages
English (en)
Hungarian (hu)
Inventor
Emily Stocking
Wolfgang Wrasidlo
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE040274(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of HUE040274T2 publication Critical patent/HUE040274T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE15705417A 2014-01-29 2015-01-28 Heteroarilamidok a proteinaggregáció inhibitoraiként HUE040274T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12

Publications (1)

Publication Number Publication Date
HUE040274T2 true HUE040274T2 (hu) 2019-03-28

Family

ID=52484559

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE18156929A HUE050964T2 (hu) 2014-01-29 2015-01-28 Heteroaril amidok mint protein aggregáció inhibitorai
HUE15705417A HUE040274T2 (hu) 2014-01-29 2015-01-28 Heteroarilamidok a proteinaggregáció inhibitoraiként

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE18156929A HUE050964T2 (hu) 2014-01-29 2015-01-28 Heteroaril amidok mint protein aggregáció inhibitorai

Country Status (38)

Country Link
US (3) US9738635B2 (OSRAM)
EP (2) EP3099684B8 (OSRAM)
JP (2) JP6619741B2 (OSRAM)
KR (1) KR102383038B1 (OSRAM)
CN (2) CN111039939B (OSRAM)
AP (1) AP2016009347A0 (OSRAM)
AU (1) AU2015211119B2 (OSRAM)
BR (2) BR122018001892B1 (OSRAM)
CA (1) CA2937967C (OSRAM)
CL (1) CL2016001918A1 (OSRAM)
CR (1) CR20160394A (OSRAM)
CY (2) CY1120348T1 (OSRAM)
DK (2) DK3099684T3 (OSRAM)
EA (1) EA032374B1 (OSRAM)
EC (1) ECSP16070327A (OSRAM)
ES (2) ES2808978T3 (OSRAM)
HK (1) HK1231470A1 (OSRAM)
HR (2) HRP20180813T1 (OSRAM)
HU (2) HUE050964T2 (OSRAM)
IL (1) IL246987B (OSRAM)
LT (2) LT3348556T (OSRAM)
ME (1) ME03800B (OSRAM)
MX (1) MX2016009896A (OSRAM)
MY (1) MY187450A (OSRAM)
NZ (1) NZ722487A (OSRAM)
PE (1) PE20161393A1 (OSRAM)
PH (1) PH12016501493B1 (OSRAM)
PL (2) PL3348556T3 (OSRAM)
PT (2) PT3099684T (OSRAM)
RS (2) RS60547B1 (OSRAM)
SA (1) SA516371579B1 (OSRAM)
SG (1) SG11201606108RA (OSRAM)
SI (2) SI3099684T1 (OSRAM)
SM (2) SMT201800318T1 (OSRAM)
TR (1) TR201809440T4 (OSRAM)
UA (1) UA118209C2 (OSRAM)
WO (1) WO2015116663A1 (OSRAM)
ZA (1) ZA201605246B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201809440T4 (tr) 2014-01-29 2018-07-23 Ucb Biopharma Sprl Protein agregasyonunun inhibitörleri olarak heteroaril amidler.
ES2885049T3 (es) * 2015-07-29 2021-12-13 UCB Biopharma SRL Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
CN107625767A (zh) * 2016-11-25 2018-01-26 刘淑兰 一种治疗慢性盆腔炎的药物
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
EA201991753A1 (ru) 2017-01-26 2020-01-14 Юсб Байофарма Спрл Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков
KR20190111080A (ko) * 2017-01-26 2019-10-01 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 비스-헤테로아릴 유도체
ES2884145T3 (es) * 2017-01-26 2021-12-10 UCB Biopharma SRL Derivados bicíclicos de bis-heteroarilo como moduladores de la agregación de proteínas
AU2018265584B2 (en) * 2017-05-12 2023-09-28 Ludwig-Maximilians-Universität München Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
CA3108484A1 (en) 2017-08-04 2019-02-07 Anthony Stewart Campbell Inhibitors of microbially induced amyloid
WO2019089640A1 (en) * 2017-10-31 2019-05-09 Loma Linda University Methods for treating traumatic brain injury
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
WO2023125376A1 (zh) 2021-12-27 2023-07-06 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
CN120265630A (zh) * 2022-11-02 2025-07-04 Ac免疫有限公司 用于诊断tdp-43蛋白质病的新化合物
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
EP1565446A1 (en) * 2002-11-28 2005-08-24 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
DK1697371T3 (da) * 2003-12-19 2007-09-17 Bristol Myers Squibb Co Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
AP2373A (en) * 2004-08-26 2012-03-07 Pfizer Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
AU2005287692B2 (en) * 2004-09-20 2012-07-12 4Sc Ag Novel heterocyclic NF-kappaB inhibitors
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
US20100168102A9 (en) * 2005-07-11 2010-07-01 Devgen Nv Amide Derivatives as Kinase Inhibitors
BRPI0614188A2 (pt) * 2005-07-29 2011-03-15 4Sc Ag compostos inibidores heterocìclicos de nf-kappab, uso dos mesmos e composição farmacêutica
BRPI0709595A2 (pt) * 2006-03-15 2011-07-19 4Sc Ag inibidores de nf-kapab heterocìclicos
EP2081892A4 (en) * 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
CA2776480A1 (en) * 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
WO2011084642A1 (en) * 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
CN104363903A (zh) 2012-03-28 2015-02-18 神经孔疗法股份有限公司 用作蛋白聚集抑制剂的苯基脲和苯基氨基甲酸盐/酯衍生物
EP2872143B1 (en) * 2012-07-16 2017-12-13 Neuropore Therapies, Inc. Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
TR201809440T4 (tr) 2014-01-29 2018-07-23 Ucb Biopharma Sprl Protein agregasyonunun inhibitörleri olarak heteroaril amidler.
ES2885049T3 (es) 2015-07-29 2021-12-13 UCB Biopharma SRL Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
ES2884145T3 (es) 2017-01-26 2021-12-10 UCB Biopharma SRL Derivados bicíclicos de bis-heteroarilo como moduladores de la agregación de proteínas
KR20190111080A (ko) 2017-01-26 2019-10-01 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 비스-헤테로아릴 유도체

Also Published As

Publication number Publication date
EA032374B1 (ru) 2019-05-31
PL3348556T3 (pl) 2020-11-02
BR112016017344B1 (pt) 2023-05-16
EP3348556A1 (en) 2018-07-18
SMT201800318T1 (it) 2018-07-17
ES2808978T3 (es) 2021-03-02
HRP20201107T8 (hr) 2020-12-11
US9738635B2 (en) 2017-08-22
US11078196B2 (en) 2021-08-03
JP2019163321A (ja) 2019-09-26
DK3099684T3 (en) 2018-07-16
HK1231470A1 (zh) 2017-12-22
MY187450A (en) 2021-09-22
KR20160113287A (ko) 2016-09-28
MX2016009896A (es) 2017-01-11
HRP20201107T1 (hr) 2020-10-30
BR112016017344A2 (pt) 2017-10-03
EP3099684B1 (en) 2018-04-04
US20190308965A1 (en) 2019-10-10
AP2016009347A0 (en) 2016-07-31
CR20160394A (es) 2016-11-01
PL3099684T3 (pl) 2018-09-28
WO2015116663A8 (en) 2016-09-15
CN106132960A (zh) 2016-11-16
SG11201606108RA (en) 2016-08-30
BR122018001892B1 (pt) 2023-05-02
AU2015211119A8 (en) 2016-12-15
SMT202000376T1 (it) 2020-09-10
CN106132960B (zh) 2019-12-17
CN111039939B (zh) 2023-09-19
US20160207912A1 (en) 2016-07-21
EP3099684A1 (en) 2016-12-07
LT3348556T (lt) 2020-08-10
EA201691529A1 (ru) 2017-01-30
CL2016001918A1 (es) 2017-01-13
PH12016501493A1 (en) 2017-02-06
PE20161393A1 (es) 2017-01-08
EP3348556B1 (en) 2020-04-29
CY1120348T1 (el) 2019-07-10
CA2937967A1 (en) 2015-08-06
SI3348556T1 (sl) 2020-10-30
AU2015211119B2 (en) 2019-05-30
RS57533B1 (sr) 2018-10-31
AU2015211119A1 (en) 2016-08-11
EP3099684B8 (en) 2018-07-04
ZA201605246B (en) 2022-05-25
LT3099684T (lt) 2018-06-25
NZ722487A (en) 2022-04-29
IL246987B (en) 2021-12-01
RS60547B1 (sr) 2020-08-31
HRP20180813T1 (hr) 2018-07-27
CN111039939A (zh) 2020-04-21
SI3099684T1 (en) 2018-08-31
HUE050964T2 (hu) 2021-01-28
PT3099684T (pt) 2018-10-22
CA2937967C (en) 2022-07-26
ES2675301T3 (es) 2018-07-10
TR201809440T4 (tr) 2018-07-23
DK3348556T3 (da) 2020-08-03
ECSP16070327A (es) 2018-05-31
JP2017505779A (ja) 2017-02-23
ME03800B (me) 2021-04-20
US20180093979A1 (en) 2018-04-05
IL246987A0 (en) 2016-09-29
ES2808978T8 (es) 2021-03-22
KR102383038B1 (ko) 2022-04-05
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
SA516371579B1 (ar) 2019-07-16
US10358443B2 (en) 2019-07-23
CY1123374T1 (el) 2021-12-31
JP6619741B2 (ja) 2019-12-11
PH12016501493B1 (en) 2017-02-06
PT3348556T (pt) 2020-07-27
JP6783900B2 (ja) 2020-11-11

Similar Documents

Publication Publication Date Title
HUE040274T2 (hu) Heteroarilamidok a proteinaggregáció inhibitoraiként
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3119772T3 (da) Heteroaryl syk-hæmmere
LT3160956T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
LT3164380T (lt) Lizinui specifiniai demetilazės-1 inhibitoriai
DK3191487T3 (da) Spirocykliske cathepsin-c-inhibitorer
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
LT3237432T (lt) Baltymo gamyba
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3132009T3 (da) Fremgangsmåde
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3099791T3 (da) Protein
LT3212237T (lt) Metotreksato vaistinė forma
HRP20181441T1 (hr) Inhibitori sintaze aldosterona
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3143018T3 (da) Carboxamidderivater
MA41266A (fr) Cataplasme
HRP20182029T1 (hr) Uti-fuzijski proteini
DK3099793T3 (da) Protein
LT3097076T (lt) Nauji cip-eikozanoidų dariniai
TH1501006052A (th) สารยับยั้ง bacei
LT3183264T (lt) Pegilinimo būdas